Haemonetics Corporation has appointed Martin Madaus to its board of directors, effective 24 July 2026. The Boston-based medical technology company focuses on delivering medical solutions for better patient outcomes. Madaus brings over 30 years of leadership experience in diagnostics and life sciences. He currently serves as senior operating executive at The Carlyle Group, where he has advised on healthcare investments since 2019. Previously, he led Ortho Clinical Diagnostics as chairman and CEO following its separation from Johnson & Johnson, and headed Millipore Corporation's transformation before its 2010 acquisition by Merck KGaA. He also chairs Repligen Corporation's board and serves on Azenta's board. Madaus holds veterinary medicine degrees from German universities.

MTD Micro Molding promotes John Clark to CEO. The longtime MTD leader returned to guide its next era of innovation and operational excellence in precision micro manufacturing. June 15, 2026 Associate Editor MTD Micro Molding revealed that it has named John Clark as its new CEO, effective June 10. Clark boasts over two decades of expertise in tooling, operations, and high-precision medical manufacturing. He also brings a deep, firsthand understanding of the steps needed to reliably produce increasingly complex miniaturized components, the company said. He first joined MTD in 2008 as a toolmaker and became a key leader, overseeing completion of the facility addition that doubled the company's manufacturing footprint. His return earlier this year began as director of operations before MTD appointed him as CEO. The company said that he returned because he believes "there's no team in the industry that does what MTD does." "Customers today are more informed about micro molding than ever," said Clark, "asking detailed questions about equipment, process discipline, and technical capabilities. What they're looking for is what MTD has been developing for decades. This isn't a new niche for us. We're the ones who defined - and continue to redefine - what this work requires." Clark's appointment comes less than a month after MTD announced former Haemonetics executive Chad Nikel would lead the company. In a statement to MPO, MTD said Nikel resigned to pursue another opportunity. The company said it recently optimized what might be the smallest overmold design in its 50-year history. In 2026's first five months, MTD produced four million components across 45 production molds, including tiny orthopedic implants with dead-sharp tips, thin-wall components for minimally invasive procedures, bioresorbable implants, and intricate multi-step overmolded devices. The company also reactivated internal lab and testing equipment to advance materials analysis capabilities, supporting more precise polymer characterization across complex programs. "By investing ahead of industry needs and developing capabilities before they're required," said Clark, "we help our customers bring the next generation of medical devices to market with confidence." "Dennis used to say that what made MTD special was the team's mentality - taking on the projects that start with some element of impossibility and finding a way to conquer them," said Darlene Tully, owner of MTD Micro Molding. "John has carried that mentality throughout his career here. He doesn't make promises he can't keep, and he builds teams and processes that deliver on the ones he does. That's the foundation of every customer relationship MTD has, and it's why I trust him to lead this company Ever Forward."